| | Indications | Recommended dosage | Side effects | Comments | Ref. |
| First-line drugs | TCAs | All types of NP | Amitriptyline: 10-150 mg/day | Dry mouth, constipation, urinary retention, orthostatic hypotension | Moderate quality of evidence; strong recommendation | [2, 12, 13, 36, 74] |
| Gabapentinoids | All types of NP | Gabapentin: 300-3600 mg/day Pregabalin: 150-600 mg/day | Dizziness, sedation, peripheral swelling | High quality of evidence; strong recommendation | [2, 12, 13, 36, 74] |
| SNRIs | All types of NP | Duloxetine: 20-120 mg/day Venlafaxine: 150-225 mg/day | Nausea | High quality of evidence; strong recommendation | [2, 12, 13, 36, 74] |
| Anticonvulsants (sodium ion channel blockers) | Trigeminal neuralgia | Carbamazepine: 200-400 mg/day Oxcarbazepine: 300-600 mg/day | Sedation, hepatotoxicity, hyponatraemia | GRADE recommendation is not applicable | [2, 12, 13, 36, 74] |
| Second-line drugs | Weak opioids | All types of NP | Tramadol: 25-400 mg/day Tapentadol: 50-600 mg/day | Nausea, vomiting, constipation | Moderate quality of evidence; weak recommendation | [2, 12, 13, 36, 74] |
| Topical agents | Peripheral NP | Lidocaine (5%) plaster Capsaicin (8%) patch | Erythema, itching | Lidocaine (5%) plaster: low quality of evidence; weak recommendation; capsaicin (8%) patch: high quality of evidence; weak recommendation | [2, 12, 13, 36, 74] |
| Third-line drugs | Strong opioids | All types of NP | Morphine: 10-120 mg/day Oxycodone: 10-120 mg/day | Nausea, vomiting, constipation | Moderate quality of evidence; weak recommendation | [2, 12, 13, 36, 74] |
| Neurotoxin | Peripheral NP | Botulinum toxin type A | Pain at injection site | Low quality of evidence; weak recommendation | [2, 12, 13, 36, 74] |
|
|